Edition:
India

Fujifilm Holdings Corp (4901.T)

4901.T on Tokyo Stock Exchange

5,397JPY
23 Oct 2020
Change (% chg)

¥35 (+0.65%)
Prev Close
¥5,362
Open
¥5,400
Day's High
¥5,418
Day's Low
¥5,373
Volume
1,344,200
Avg. Vol
1,829,745
52-wk High
¥6,420
52-wk Low
¥4,152

Latest Key Developments (Source: Significant Developments)

Dr. Reddy's Prices COVID-19 Drug Avigan (Favipiravir) at 99 Rupees/Tablet
Wednesday, 19 Aug 2020 

Aug 19 (Reuters) - Dr. Reddy's Laboratories Ltd executives at press briefing::IN TALKS WITH REGULATORS IN MULTIPLE COUNTRIES TO LAUNCH FUJIFILM'S <<<4901.T>>> AVIGAN (FAVIPIRAVIR) FOR COVID-19.TO PURSUE AVIGAN APPROVAL FOR COVID-19 FIRST IN EMERGING MARKETS, THEN DEVELOPED MARKETS.SETS PRICE OF 99 RUPEES ($1.32) PER 200 MG TABLET OF AVIGAN (FAVIPIRAVIR) IN INDIA.HOPES TO LAUNCH GILEAD'S <<>> REMDESIVIR FOR COVID-19 IN INDIA BY FIRST WEEK OF SEPT.HOPES TO SEEK FAST-TRACK APPROVAL FOR AVIGAN (FAVIPIRAVIR) IN U.S..HAS ENOUGH MANUFACTURING CAPACITY FOR AVIGAN TO SERVE BOTH EMERGING, DEVELOPED MARKETS.  Full Article

Fujifilm Says Delay In Completion Schedule For Acquisition Of Diagnostic Imaging-Related Business From Hitachi
Thursday, 28 May 2020 

May 28 (Reuters) - Fujifilm Holdings Corp <4901.T>::CHANGE IN COMPLETION SCHEDULE FOR ACQUISITION OF DIAGNOSTIC IMAGING-RELATED BUSINESS FROM HITACHI.COMPLETION SCHEDULE DELAYED DUE TO COVID-19 SITUATION, NOW NOT YET DETERMINED.  Full Article

Fujifilm's Anti-Flu Avigan Not Showing Apparent Efficacy In Coronavirus Treatment - Kyodo News
Tuesday, 19 May 2020 

May 19 (Reuters) - :FUJIFILM'S ANTI-FLU AVIGAN NOT SHOWING APPARENT EFFICACY IN CORONAVIRUS TREATMENT - KYODO NEWS, CITING SOURCES.  Full Article

Fujifilm Holdings Corp - To Buy Back Up To 1.07% Of Own Shares Worth 15 Billion Yen
Monday, 16 Mar 2020 

Fujifilm Holdings Corp <4901.T>::FUJIFILM HOLDINGS CORP - TO BUY BACK UP TO 1.07% OF OWN SHARES WORTH 15 BILLION YEN.  Full Article

Xerox Says Restructures FUJIFILM Relationship, Will Receive $2.3 Bln from Related Transactions
Tuesday, 5 Nov 2019 

Nov 5 (Reuters) - Xerox Holdings Corp ::EXPECTS TO PROVIDE UPDATED 2019 GUIDANCE BY MID-DECEMBER 2019 THAT INCORPORATES IMPACT OF TRANSACTIONS (REMOVES EXTRANEOUS WORD).XEROX RESTRUCTURES FUJIFILM RELATIONSHIP, WILL RECEIVE $2.3B FROM RELATED TRANSACTIONS.SALE OF XEROX'S 25% STAKE IN FUJI XEROX CO., LTD. (FX) TO A SUBSIDIARY OF FUJIFILM;.SALE OF XEROX'S 25% STAKE IN FUJI XEROX CO., LTD. (FX) TO A SUBSIDIARY OF FUJIFILM.MODIFIED SOURCING TERMS FOR FUTURE PRODUCT PROGRAMS THAT WILL ENSURE XEROX'S PRODUCT SUPPLY CONTINUITY.DISMISSAL OF $1 BILLION LAWSUIT FUJIFILM FILED AGAINST XEROX AFTER LAST YEAR'S TERMINATED MERGER.XEROX EXPECTS TO PROVIDE UPDATED 2019 GUIDANCE BY MID-DECEMBER 2019 THAT INCORPORATES IMPACT OF TRANSACTIONS.  Full Article

Xerox Restructures Fujifilm Relationship, Will Receive $2.3B From Related Transactions
Tuesday, 5 Nov 2019 

Nov 5 (Reuters) - Xerox Holdings Corp ::XEROX RESTRUCTURES FUJIFILM RELATIONSHIP, WILL RECEIVE $2.3B FROM RELATED TRANSACTIONS.SALE OF XEROX'S 25% STAKE IN FUJI XEROX CO., LTD. (FX) TO A SUBSIDIARY OF FUJIFILM;.SALE OF XEROX'S 25% STAKE IN FUJI XEROX CO., LTD. (FX) TO A SUBSIDIARY OF FUJIFILM.MODIFIED SOURCING TERMS FOR FUTURE PRODUCT PROGRAMS THAT WILL ENSURE XEROX'S PRODUCT SUPPLY CONTINUITY.QTRLY EXPECTS TO PROVIDE UPDATED 2019 GUIDANCE BY MID-DECEMBER 2019 THAT INCORPORATES IMPACT OF TRANSACTIONS.DISMISSAL OF $1 BILLION LAWSUIT FUJIFILM FILED AGAINST XEROX AFTER LAST YEAR'S TERMINATED MERGER.XEROX EXPECTS TO PROVIDE UPDATED 2019 GUIDANCE BY MID-DECEMBER 2019 THAT INCORPORATES IMPACT OF TRANSACTIONS.  Full Article

CSG Flags Takeover Offer From Fuji Xerox
Thursday, 24 Oct 2019 

Oct 24 (Reuters) - CSG Ltd ::CSG LTD - FUJI XEROX PROPOSES TO ACQUIRE CSG IN A RECOMMENDED TRANSACTION.CSG LTD - CASH PRICE OF A$0.31 PER CSG SHARE.CSG LTD - EACH MEMBER OF CSG BOARD RECOMMENDS THAT CSG SHAREHOLDERS VOTE IN FAVOUR OF SCHEME IN ABSENCE OF A SUPERIOR PROPOSAL.CSG LTD - CONSIDERATION VALUES CSG'S ISSUED EQUITY AT A$140.8 MILLION AND ENTERPRISE VALUE AT A$181.6 MILLION.  Full Article

FDA Recommends Health Care Facilities, Manufacturers Transition To Duodenoscopes With Disposable Components
Thursday, 29 Aug 2019 

Aug 29 (Reuters) - FDA::FDA RECOMMENDS HEALTH CARE FACILITIES AND MANUFACTURERS BEGIN TRANSITIONING TO DUODENOSCOPES WITH DISPOSABLE COMPONENTS TO REDUCE RISK OF PATIENT INFECTION.FDA SAYS WARNS ABOUT CERTAIN TEST STRIPS ILLEGALLY MARKETED TO ASSESS DUODENOSCOPE CLEANLINESS.FDA SAYS ORDERS NEW POSTMARKET STUDIES FOR MANUFACTURERS, REQUESTS REAL-WORLD CONTAMINATION RATES IN DUODENOSCOPE LABELING.FDA SAYS CONTINUE TO WORK WITH MANUFACTURERS TO INCREASE SUPPLY OF DISPOSABLE CAP DUODENOSCOPES.FDA - RECOMMENDING HEALTH CARE FACILITIES TRANSITION AWAY FROM FIXED ENDCAP MODELS INCLUDING OLYMPUS CORPORATION'S TJF-Q160, TJF-Q180V, PJF-160 & JF-140F.FDA - RECOMMENDING HEALTH CARE FACILITIES TRANSITION FROM FIXED ENDCAP MODELS INCLUDING FUJIFILM MEDICAL SYSTEMS USA'S ED-530XT, PENTAX MEDICAL'S ED-3490TK.  Full Article

Fujifilm To Buy Back Up To 3.18% Of Shares Worth 50 Billion Yen Through March 31, 2020
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Fujifilm Holdings Corp <4901.T>::TO BUY BACK UP TO 3.18% OF SHARES WORTH 50 BILLION YEN THROUGH MARCH 31, 2020.  Full Article

Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerod, Denmark to Fujifilm
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Biogen Inc ::BIOGEN EXPECTS NEW MANUFACTURING FACILITY IN SOLOTHURN, SWITZERLAND TO BE OPERATIONAL BY END OF 2020.BIOGEN ENTERS INTO AN AGREEMENT TO SELL ITS LARGE-SCALE BIOLOGICS MANUFACTURING SITE IN HILLERØD, DENMARK TO FUJIFILM.BIOGEN WILL ENTER INTO MANUFACTURING SERVICES AGREEMENTSWITH FUJIFILM TO SUPPLY TYSABRI AND THIRD-PARTY PRODUCTS.BIOGEN EXPECTS NEW MANUFACTURING FACILITY IN SOLOTHURN, SWITZERLAND TO BE OPERATIONAL BY END OF 2020.BIOGEN- EXPECTS TO RECORD TOTAL AFTER-TAX LOSS IN Q1 2019 OF ABOUT $130 MILLION TO $150 MILLION, OR $0.66 TO $0.76 PER DILUTED SHARE, RELATED TO PROPOSED TRANSACTION.  Full Article

Photo

Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan

TOKYO Japan's Fujifilm Holdings Corp said on Thursday it has partnered with Shanghai-based Carelink Pharmaceutical Co to seek approval in China for Avigan to treat COVID-19 and influenza.